Douglas K. Brubaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Douglas K. Brubaker has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Brendan K. Ball
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
10 shared publications - Ran Ran
Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University; Cleveland, OH, USA
6 shared publications Smrutiti Jena
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, USA
6 shared publicationsBrendan K. Ball
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA
5 shared publications- Leopold N. Green
Weldon School of Biomedical Engineering, Purdue University, West Lafayette IN
5 shared publications - Deva D. Chan
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA
4 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Springer Nature in Cellular and Molecular Bioengineering
- p. 1-17
A Vaginal Microbiome Pharmacology Foundation Model for Microbiome-Based Drug Development and Reproductive Health Insights
Introduction: Engineering microbiome therapies requires an organizing principle for the mechanisms by which microbiome factors impact the host. We previously developed the “pharmacobiome”, a framework that uses mechanisms of drugs to quantify the host impact of microbiome factors. Here, we generalized this framework into a Microbiome Pharmacology Foundation Model (MPFM) for mechanism-informed design of microbiome therapeutics. Methods: We used correlation analysis of vaginal multi-omics data to generate host gene signatures for vaginal microbiome factors and compared the signatures to drug treatment host transcriptomics to construct microbiome factor-drug similarity scores. This Vaginal Microbiome Pharmacology database of 6,719,800 training instances enabled us to train the MPFM, a deep autoencoder model, and to derive experimentally testable predictions of individual microbiome factors and designed combination therapeutic properties. Results: The MPFM training converged with strong performance (r = 0.57, MSE = 0.0058) and the latent space formed a continuous manifold. We analyzed cisplatin in the MPFM to identify anti-cancer metabolites and experimentally confirmed that taurine was Lactobacillus- derived and cytotoxic against cancer cell lines ( p < 0.0005). We also analyzed metronidazole to identify antibiotic metabolites and experimentally showed hydroxyisocaproate was Lactobacillus- derived and selectively killed vaginal pathogens ( p < 0.05). Finally, we used the model to explore patient-specific microbiome pharmacology and design probiotic combinations to support in vitro fertilization. Conclusions: We demonstrated consistent performance of the MPFM and experimentally supported the validity of predictions. Our continued work simulates probiotic, prebiotic, and postbiotic combinations for patient-specific in vivo sample analysis to develop tailored microbiome therapies for gynecologic conditions.
- 20 October 2026
- Published by Springer Nature in Cellular and Molecular Bioengineering
- p. 1-17
Open AccessA Vaginal Microbiome Pharmacology Foundation Model for Microbiome-Based Drug Development and Reproductive Health Insights
Introduction: Engineering microbiome therapies requires an organizing principle for the mechanisms by which microbiome factors impact the host. We previously developed the “pharmacobiome”, a framework that uses mechanisms of drugs to quantify the host impact of microbiome factors. Here, we generalized this framework into a Microbiome Pharmacology Foundation Model (MPFM) for mechanism-informed design of microbiome therapeutics. Methods: We used correlation analysis of vaginal multi-omics data to generate host gene signatures for vaginal microbiome factors and compared the signatures to drug treatment host transcriptomics to construct microbiome factor-drug similarity scores. This Vaginal Microbiome Pharmacology database of 6,719,800 training instances enabled us to train the MPFM, a deep autoencoder model, and to derive experimentally testable predictions of individual microbiome factors and designed combination therapeutic properties. Results: The MPFM training converged with strong performance (r = 0.57, MSE = 0.0058) and the latent space formed a continuous manifold. We analyzed cisplatin in the MPFM to identify anti-cancer metabolites and experimentally confirmed that taurine was Lactobacillus- derived and cytotoxic against cancer cell lines ( p < 0.0005). We also analyzed metronidazole to identify antibiotic metabolites and experimentally showed hydroxyisocaproate was Lactobacillus- derived and selectively killed vaginal pathogens ( p < 0.05). Finally, we used the model to explore patient-specific microbiome pharmacology and design probiotic combinations to support in vitro fertilization. Conclusions: We demonstrated consistent performance of the MPFM and experimentally supported the validity of predictions. Our continued work simulates probiotic, prebiotic, and postbiotic combinations for patient-specific in vivo sample analysis to develop tailored microbiome therapies for gynecologic conditions.
- Open Access
- 3 July 2026
- Published by Springer Nature in npj Systems Biology and Applications
Modeling single nucleus microglia across species identifies immune pathways and therapeutic candidates in Alzheimer’s disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by memory loss and behavioral changes. A pivotal influence on AD pathology is the dysregulation of microglia in the brain. Despite promising findings in mouse models, there are limitations to the translatable biological information across species due to differences in the physiology, timeline of disease, and human heterogeneity. To address these interspecies discrepancies, we developed a novel implementation of the Translatable Components Regression (TransComp-R) framework, which integrated microglial single-nucleus transcriptomic data to identify biological pathways in mice AD models predictive of human AD. We compared model variations with sparse and traditional principal component analysis (PCA), finding that standard PCA encoded more interpretable mouse PCs compared to sPCA despite limited differences in technical performance. Mouse PCs significantly differentiated human AD from control microglial cells in the BA41/42, BA6/8, hippocampus and entorhinal cortex brain regions. However, these PCs had limited separation of human AD from control microglia in the prefrontal cortex. Additionally, we identified gene signatures from FDA-approved drugs that correlated with significant mouse component loadings, including valproic-acid and calcifediol. This computational framework may support the discovery of cross-species disease similarities, including the identification of candidate pharmacological solutions that may translate across species.
- 3 July 2026
- Published by Springer Nature in npj Systems Biology and Applications
Open AccessModeling single nucleus microglia across species identifies immune pathways and therapeutic candidates in Alzheimer’s disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by memory loss and behavioral changes. A pivotal influence on AD pathology is the dysregulation of microglia in the brain. Despite promising findings in mouse models, there are limitations to the translatable biological information across species due to differences in the physiology, timeline of disease, and human heterogeneity. To address these interspecies discrepancies, we developed a novel implementation of the Translatable Components Regression (TransComp-R) framework, which integrated microglial single-nucleus transcriptomic data to identify biological pathways in mice AD models predictive of human AD. We compared model variations with sparse and traditional principal component analysis (PCA), finding that standard PCA encoded more interpretable mouse PCs compared to sPCA despite limited differences in technical performance. Mouse PCs significantly differentiated human AD from control microglial cells in the BA41/42, BA6/8, hippocampus and entorhinal cortex brain regions. However, these PCs had limited separation of human AD from control microglia in the prefrontal cortex. Additionally, we identified gene signatures from FDA-approved drugs that correlated with significant mouse component loadings, including valproic-acid and calcifediol. This computational framework may support the discovery of cross-species disease similarities, including the identification of candidate pharmacological solutions that may translate across species.
- Open Access
- 11 April 2026
- Published by Springer Nature in Animal Microbiome
- Vol. 8 (1)
Rumenomics: evaluation of rumen metabolites from healthy sheep identifies differentially produced metabolites across sex, age, and weight
The rumen harbors a diverse and dynamic microbiome vital in digesting vegetation into metabolic byproducts for energy and general biological function. Alth
- 11 April 2026
- Published by Springer Nature in Animal Microbiome
- Vol. 8 (1)
Open AccessRumenomics: evaluation of rumen metabolites from healthy sheep identifies differentially produced metabolites across sex, age, and weight
The rumen harbors a diverse and dynamic microbiome vital in digesting vegetation into metabolic byproducts for energy and general biological function. Alth
- Open Access
Cross-Species Translation Enhances the Use of Mouse Models for Translatability and Drug Discovery in Late-Onset Alzheimer’s Disease
Alzheimer’s disease (AD) is a brain disease characterized by deposition of insoluble amyloid-β plaque, intraneuronal neurofibrillary tangles, and cognitive dysfunction. AD can be characterized as early-onset or late-onset based on age and genetic factors. For early-onset, these genetic factors can include amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2). For late-onset, these can include apolipoprotein E e4 (APOE4), and the R47H variant of triggering receptor expressed on myeloid cells 2 (TREM2). Mouse models incorporating these risk factors provide critical knowledge for studying AD pathology and preclinical studies for drug development. However, these transgenic mice depend on early-onset genetic mutations and are deficient in certain AD features that are present in late-onset. Here, we developed innovative non-linear and feature selection procedures for our cross-species translation framework, Translatable Components Regression (TransComp-R), to identify transcriptomic features in mouse models predictive of human late-onset AD pathobiology. We used the cross-species computational translatability links of TransComp-R to perform computational high-throughput drug screening and identified multiple repurposable drugs for AD treatment that targeted the sleep-wake cycle. We tested these predictions in an orthogonal, prospective cohort of human subjects treated with an orexin receptor antagonist, suvorexant. We correlated conserved protein-level biomarkers from our cross-species transcriptomics model with significant reductions in phosphorylated tau in cerebrospinal fluid collected from humans treated with suvorexant. This study demonstrates the power of computational methods like TransComp-R to enhance the utility of murine disease models for discovering new therapeutic approaches for AD. One Sentence Summary: Cross-species translation modeling across different mouse models reveals sleep-relevant drug mechanisms as potentially therapeutic for Alzheimer’s disease.
Open AccessCross-Species Translation Enhances the Use of Mouse Models for Translatability and Drug Discovery in Late-Onset Alzheimer’s Disease
Alzheimer’s disease (AD) is a brain disease characterized by deposition of insoluble amyloid-β plaque, intraneuronal neurofibrillary tangles, and cognitive dysfunction. AD can be characterized as early-onset or late-onset based on age and genetic factors. For early-onset, these genetic factors can include amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2). For late-onset, these can include apolipoprotein E e4 (APOE4), and the R47H variant of triggering receptor expressed on myeloid cells 2 (TREM2). Mouse models incorporating these risk factors provide critical knowledge for studying AD pathology and preclinical studies for drug development. However, these transgenic mice depend on early-onset genetic mutations and are deficient in certain AD features that are present in late-onset. Here, we developed innovative non-linear and feature selection procedures for our cross-species translation framework, Translatable Components Regression (TransComp-R), to identify transcriptomic features in mouse models predictive of human late-onset AD pathobiology. We used the cross-species computational translatability links of TransComp-R to perform computational high-throughput drug screening and identified multiple repurposable drugs for AD treatment that targeted the sleep-wake cycle. We tested these predictions in an orthogonal, prospective cohort of human subjects treated with an orexin receptor antagonist, suvorexant. We correlated conserved protein-level biomarkers from our cross-species transcriptomics model with significant reductions in phosphorylated tau in cerebrospinal fluid collected from humans treated with suvorexant. This study demonstrates the power of computational methods like TransComp-R to enhance the utility of murine disease models for discovering new therapeutic approaches for AD. One Sentence Summary: Cross-species translation modeling across different mouse models reveals sleep-relevant drug mechanisms as potentially therapeutic for Alzheimer’s disease.
- Open Access
Proteomic analysis reveals shared biological pathways linking acrolein to biomolecular changes in the acute phase of rat spinal cord injury
Spinal cord injury (SCI) pathology is highly difficult to treat due to substantial heterogeneity in injury presentation and spread, along with unclear mechanisms linking damage to pathology. Damages from injury forces (primary injury) are exacerbated by a series of biochemical events that follow the initial damage and injure additional tissue, known as secondary injury. Reactive aldehydes, such as acrolein, play a key role in propagating secondary injury cascades following SCI. Targeting acrolein after SCI has demonstrated therapeutic potential in limiting injury spread and pathology. However, injury mechanisms linking reactive aldehydes to SCI outcome have not been fully characterized. To gain a more comprehensive understanding of the cellular and molecular mechanisms underlying SCI, we generated proteomic profiles of rat spinal cords 24 h (acute phase) after subjection to SCI, sham injury, saline injection, or acrolein injection. We performed gene set enrichment analysis (GSEA) to characterize proteins and pathways significantly enriched after SCI and acrolein-injection. We then used Translatable Components Regression (TransComp-R), a framework for translating biological signatures across systems, to assess whether acrolein-associated spinal cord signatures can stratify SCI from sham outcomes. Our proteomics analysis revealed 467 differentially expressed proteins (DEPs) between the sham and SCI groups and 7 DEPs between saline and acrolein injection groups. Notably, the complement and coagulation cascades were upregulated in spinal cords subjected to SCI and acrolein injection. Our TransComp-R analysis further demonstrated that acrolein-associated signatures could distinguish SCI from sham conditions. Taken together, our findings suggest that acrolein induces proteomic alterations during the acute phase of SCI and is associated with complement and coagulation cascade activation, among other pathways. Therefore, this study reinforces the notion that understanding the role of acrolein in the acute phase of secondary SCI may be beneficial.
Open AccessProteomic analysis reveals shared biological pathways linking acrolein to biomolecular changes in the acute phase of rat spinal cord injury
Spinal cord injury (SCI) pathology is highly difficult to treat due to substantial heterogeneity in injury presentation and spread, along with unclear mechanisms linking damage to pathology. Damages from injury forces (primary injury) are exacerbated by a series of biochemical events that follow the initial damage and injure additional tissue, known as secondary injury. Reactive aldehydes, such as acrolein, play a key role in propagating secondary injury cascades following SCI. Targeting acrolein after SCI has demonstrated therapeutic potential in limiting injury spread and pathology. However, injury mechanisms linking reactive aldehydes to SCI outcome have not been fully characterized. To gain a more comprehensive understanding of the cellular and molecular mechanisms underlying SCI, we generated proteomic profiles of rat spinal cords 24 h (acute phase) after subjection to SCI, sham injury, saline injection, or acrolein injection. We performed gene set enrichment analysis (GSEA) to characterize proteins and pathways significantly enriched after SCI and acrolein-injection. We then used Translatable Components Regression (TransComp-R), a framework for translating biological signatures across systems, to assess whether acrolein-associated spinal cord signatures can stratify SCI from sham outcomes. Our proteomics analysis revealed 467 differentially expressed proteins (DEPs) between the sham and SCI groups and 7 DEPs between saline and acrolein injection groups. Notably, the complement and coagulation cascades were upregulated in spinal cords subjected to SCI and acrolein injection. Our TransComp-R analysis further demonstrated that acrolein-associated signatures could distinguish SCI from sham conditions. Taken together, our findings suggest that acrolein induces proteomic alterations during the acute phase of SCI and is associated with complement and coagulation cascade activation, among other pathways. Therefore, this study reinforces the notion that understanding the role of acrolein in the acute phase of secondary SCI may be beneficial.
- Open Access
Risk of HSV-2 Acquisition Among Women with Bacterial Vaginosis: Systematic Review and Meta-Analysis
Objective: Bacterial vaginosis is a dysbiosis of the vaginal microbiome, typically characterized by a loss of Lactobacillus. Lactobacillus plays a crucial role in vaginal immunity and protection against sexually transmitted infections. Herpes simplex virus 2, the primary cause of genital herpes, impacts 13% of people worldwide. We undertook this systematic review and meta-analysis to examine the risk of herpes simplex virus 2 acquisition in women with bacterial vaginosis. Secondarily, we examined the impact of bacterial vaginosis on herpes simplex virus 2 shedding, reactivation, and symptoms. Data sources: We searched PubMed, EMBASE, Cochrane, Web of Science, Google Scholar, and ClinicalTrials.gov for articles published before 1 July 2023 for microbiome and herpes simplex virus type 2. Studies were limited to human subjects and the English language. An updated search was performed in January 2026. This study was registered on PROSPERO (CRD42023439139). Methods of study selection: Studies on non-pregnant, reproductive-aged cisgender women that diagnosed bacterial vaginosis by Amsel Criteria, Nugent Scoring or used molecular techniques, and those that detected herpes simplex virus 2 by serological assay or PCR testing were included. Our search identified 863 results with four publications eligible for inclusion. For our secondary outcomes, 40 results were identified regarding herpes simplex virus 2 shedding, with two publications eligible for inclusion, which did not meet our threshold for meta-analysis. There were 21 results identified for herpes simplex virus 2 reaction and 115 results for herpes simplex virus 2 symptoms, with no articles being eligible for inclusion. Tabulation, integration, and results: Quality assessment was performed following data extraction using the quality assessment scales from the Joanna Briggs Institute. Results were extracted, and the pooled hazard ratio was calculated with 95% confidence interval. A total of 1906 women were included in this analysis, and 255 acquired herpes simplex virus 2. The pooled unadjusted hazard ratios produced an effect size of 1.91, (95% confidence interval 1.4649–2.4980), and a p-value of p-value of 0.0001 indicating that bacterial vaginosis is associated with a increased risk of herpes simplex virus 2 acquisition. Conclusions: This systematic review with meta-analysis indicates that bacterial vaginosis is associated with a significantly increased risk (91% unadjusted, 85% adjusted) of herpes simplex virus 2 acquisition, indicating that bacterial vaginosis treatment may reduce herpes simplex virus 2 acquisition. A notable limitation of these findings is the relatively small number of studies eligible for inclusion in this systematic review and meta-analysis.
Open AccessRisk of HSV-2 Acquisition Among Women with Bacterial Vaginosis: Systematic Review and Meta-Analysis
Objective: Bacterial vaginosis is a dysbiosis of the vaginal microbiome, typically characterized by a loss of Lactobacillus. Lactobacillus plays a crucial role in vaginal immunity and protection against sexually transmitted infections. Herpes simplex virus 2, the primary cause of genital herpes, impacts 13% of people worldwide. We undertook this systematic review and meta-analysis to examine the risk of herpes simplex virus 2 acquisition in women with bacterial vaginosis. Secondarily, we examined the impact of bacterial vaginosis on herpes simplex virus 2 shedding, reactivation, and symptoms. Data sources: We searched PubMed, EMBASE, Cochrane, Web of Science, Google Scholar, and ClinicalTrials.gov for articles published before 1 July 2023 for microbiome and herpes simplex virus type 2. Studies were limited to human subjects and the English language. An updated search was performed in January 2026. This study was registered on PROSPERO (CRD42023439139). Methods of study selection: Studies on non-pregnant, reproductive-aged cisgender women that diagnosed bacterial vaginosis by Amsel Criteria, Nugent Scoring or used molecular techniques, and those that detected herpes simplex virus 2 by serological assay or PCR testing were included. Our search identified 863 results with four publications eligible for inclusion. For our secondary outcomes, 40 results were identified regarding herpes simplex virus 2 shedding, with two publications eligible for inclusion, which did not meet our threshold for meta-analysis. There were 21 results identified for herpes simplex virus 2 reaction and 115 results for herpes simplex virus 2 symptoms, with no articles being eligible for inclusion. Tabulation, integration, and results: Quality assessment was performed following data extraction using the quality assessment scales from the Joanna Briggs Institute. Results were extracted, and the pooled hazard ratio was calculated with 95% confidence interval. A total of 1906 women were included in this analysis, and 255 acquired herpes simplex virus 2. The pooled unadjusted hazard ratios produced an effect size of 1.91, (95% confidence interval 1.4649–2.4980), and a p-value of p-value of 0.0001 indicating that bacterial vaginosis is associated with a increased risk of herpes simplex virus 2 acquisition. Conclusions: This systematic review with meta-analysis indicates that bacterial vaginosis is associated with a significantly increased risk (91% unadjusted, 85% adjusted) of herpes simplex virus 2 acquisition, indicating that bacterial vaginosis treatment may reduce herpes simplex virus 2 acquisition. A notable limitation of these findings is the relatively small number of studies eligible for inclusion in this systematic review and meta-analysis.
- Open Access
- 29 January 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (2) , 116916
Systems mapping of intra-donor, cross-tissue T cell clonal expansion and tissue adaptation in the gut-liver-blood axis
- 29 January 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (2) , 116916
Open AccessSystems mapping of intra-donor, cross-tissue T cell clonal expansion and tissue adaptation in the gut-liver-blood axis
- Open Access
- 13 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1715827
A ligand-centered framework for γδ T cell activation in colorectal cancer revealed by single-cell and transformer-based perturbation
Understanding the activation mechanisms of γδ T cells in colorectal cancer (CRC) is critical for harnessing their therapeutic potential. Here, using an atlas of human CRC-infiltrating γδ T cells that we built by integrating multiple single-cell RNA-seq datasets, we developed a γδ T cell-refined ligand inference pipeline by combining differential gene expression, gene regulatory network prediction, ligand inference, and in silico perturbation analysis. This approach identified ligands, including IL-15 and TNFSF9 (4-1BBL), as candidates promoting γδ T cell effector function and highlighted NCR2 and KLRC3 (NKG2E), whose in silico overexpression was associated with γδ T cell activation. Ligand enrichment analyses further indicated that monocytes and dendritic cells are key contributors to γδ T cell activation in the tumor microenvironment. Our results also highlighted transcription factors IKZF1, FOSL2, and FOXO1 in the less activated γδ T cells and IRF1, KLF2, and BHLHE40 in the effector γδ T cells that plausibly regulated the differential activation state. Together, our results offer a systems-level view of the signaling and transcriptional programs governing γδ T cell phenotypes in CRC and provide a foundation for γδ T cell-based immunotherapies with enhanced antitumor functions.
- 13 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1715827
Open AccessA ligand-centered framework for γδ T cell activation in colorectal cancer revealed by single-cell and transformer-based perturbation
Understanding the activation mechanisms of γδ T cells in colorectal cancer (CRC) is critical for harnessing their therapeutic potential. Here, using an atlas of human CRC-infiltrating γδ T cells that we built by integrating multiple single-cell RNA-seq datasets, we developed a γδ T cell-refined ligand inference pipeline by combining differential gene expression, gene regulatory network prediction, ligand inference, and in silico perturbation analysis. This approach identified ligands, including IL-15 and TNFSF9 (4-1BBL), as candidates promoting γδ T cell effector function and highlighted NCR2 and KLRC3 (NKG2E), whose in silico overexpression was associated with γδ T cell activation. Ligand enrichment analyses further indicated that monocytes and dendritic cells are key contributors to γδ T cell activation in the tumor microenvironment. Our results also highlighted transcription factors IKZF1, FOSL2, and FOXO1 in the less activated γδ T cells and IRF1, KLF2, and BHLHE40 in the effector γδ T cells that plausibly regulated the differential activation state. Together, our results offer a systems-level view of the signaling and transcriptional programs governing γδ T cell phenotypes in CRC and provide a foundation for γδ T cell-based immunotherapies with enhanced antitumor functions.
- Open Access
- 12 January 2026
- Published by Springer Nature in npj Microgravity
- Vol. 12 (1)
Integrated cross-species translation and biophysical multi-scale modeling links molecular signatures and locomotory phenotypes in spaceflight-induced sarcopenia
Age-related skeletal muscle deterioration, referred to as sarcopenia, poses significant risks to astronaut health and mission success during spaceflight, yet its multisystem drivers remain poorly understood. While terrestrial sarcopenia manifests gradually through aging, spaceflight induces analogous musculoskeletal decline within weeks, providing an accelerated model to study conserved atrophy mechanisms. Here, we introduced an integrative framework combining cross-species genetic analysis with physiological modeling to understand mechanistic pathways in space-induced sarcopenia. By analyzing rodent and human datasets, we identified conserved molecular pathways underlying spaceflight-induced muscle atrophy, revealing shared regulators of neuromuscular signaling including pathways related to neurotransmitter release and regulation, mitochondrial function, and synaptic integration. Building upon these molecular insights, we developed a physiologically grounded central pattern generator model that reproduced spaceflight-induced locomotion deficits in mice. This multi-scale approach established mechanistic connections between transcriptional changes and impaired movement kinetics while identifying potential therapeutic targets applicable to both spaceflight and terrestrial aging-related muscle loss.
- 12 January 2026
- Published by Springer Nature in npj Microgravity
- Vol. 12 (1)
Open AccessIntegrated cross-species translation and biophysical multi-scale modeling links molecular signatures and locomotory phenotypes in spaceflight-induced sarcopenia
Age-related skeletal muscle deterioration, referred to as sarcopenia, poses significant risks to astronaut health and mission success during spaceflight, yet its multisystem drivers remain poorly understood. While terrestrial sarcopenia manifests gradually through aging, spaceflight induces analogous musculoskeletal decline within weeks, providing an accelerated model to study conserved atrophy mechanisms. Here, we introduced an integrative framework combining cross-species genetic analysis with physiological modeling to understand mechanistic pathways in space-induced sarcopenia. By analyzing rodent and human datasets, we identified conserved molecular pathways underlying spaceflight-induced muscle atrophy, revealing shared regulators of neuromuscular signaling including pathways related to neurotransmitter release and regulation, mitochondrial function, and synaptic integration. Building upon these molecular insights, we developed a physiologically grounded central pattern generator model that reproduced spaceflight-induced locomotion deficits in mice. This multi-scale approach established mechanistic connections between transcriptional changes and impaired movement kinetics while identifying potential therapeutic targets applicable to both spaceflight and terrestrial aging-related muscle loss.